Inflammatory reactions in HIV-1-infected persons after initiation of highly active antiretroviral therapy

Citation
Ja. Desimone et al., Inflammatory reactions in HIV-1-infected persons after initiation of highly active antiretroviral therapy, ANN INT MED, 133(6), 2000, pp. 447-454
Citations number
94
Categorie Soggetti
General & Internal Medicine","Medical Research General Topics
Journal title
ANNALS OF INTERNAL MEDICINE
ISSN journal
00034819 → ACNP
Volume
133
Issue
6
Year of publication
2000
Pages
447 - 454
Database
ISI
SICI code
0003-4819(20000919)133:6<447:IRIHPA>2.0.ZU;2-C
Abstract
Purpose: To review reported inflammatory reactions occurring after initiati on of highly active antiretroviral therapy (HAART) in persons infected with HIV-1 and to explore the mechanisms leading to these reactions. Data Sources: MEDLINE search of biomedical literature reporting inflammator y reactions after HAART. Bibliographies of retrieved reports were also revi ewed. Study Selection: Articles describing patients infected with HIV-1 who had i mmunologic and virologic responses to HAART and subsequently developed infl ammatory reactions. Data Extraction: Data on the immune status, clinical characteristics, and t herapeutic management of patients who were seropositive for HIV-1 and had i nflammatory reactions after HAART. Data Synthesis: Inflammatory reactions involving opportunistic infections, AIDS-associated malignant conditions, and other non-infectious diseases hav e recently been described in patients infected with HIV-1. These conditions often appeared shortly after the introduction of HAART and were associated with pronounced reductions in plasma HIV-1 viral load and increases in CD4 (+) T-lymphocyte counts. Clinical presentation was often atypical of that i n patients with untreated HIV-1 infection, probably because of restored imm unity. Most cases improved despite continuation of HAART, although some pat ients required anti-inflammatory drugs or specific antimicrobial agents. Conclusions: Clinicians caring for patients who are infected with HIV-1 and receiving HAART must be aware of this new and diverse clinical syndrome. A s more HAART recipients are studied. new presentations will probably be obs erved.